(Q43594181)
Statements
Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B (English)
D M Savarese
V Hars
W L Akerley
M E Taplin
P A Godley
A Hussain
E J Small
N J Vogelzang